Cytek Biosciences to Participate at the Goldman Sachs 45th Annual Global Healthcare Conference
Cytek Biosciences to Participate at the Goldman Sachs 45th Annual Global Healthcare Conference
FREMONT, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL.
加州弗里蒙特,2024年5月30日(环球新闻社)- Cytek Biosciences,Inc.(纳斯达克: CTKB)是一家领先的细胞分析解决方案公司,今天宣布该公司将参加即将在佛罗里达州迈阿密海滩举行的高盛第45届全球医疗保健大会。thCytek管理层计划于6月12日星期三上午9:20参加“炉边聊天”。东部时间/太平洋时间城市感兴趣的各方可以在公司网站的“投资者”部分访问演示文稿的实时和存档网络广播:investors.cytekbio.com。
Cytek management is scheduled to participate in a fireside chat on Wednesday, June 12th at 9:20 a.m. Eastern Time / 6:20 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com.
关于Cytek Biosciences,Inc.thCytek Biosciences(纳斯达克: CTKB)是一家领先的细胞分析解决方案公司,通过使用其专利的全光谱分析(FSP)技术提供高分辨率、高内容和高灵敏度的细胞分析,推动下一代细胞分析工具的发展。Cytek的新方法利用发光信号整个光谱内的信息,以实现更高水平的多重检测精度和敏感度。 Cytek的FSP平台包括其核心仪器Cytek Aurora和Northern Lights系统;其细胞分选机Cytek Aurora CS;Amnis和Guava品牌下的流式细胞仪和成像产品;Cytek Orion试剂混合制备系统以及试剂、软件和服务,为其客户提供综合集成的解决方案套件。 Cytek总部位于加利福尼亚弗里蒙特,并在全球范围内设有办事处和分销渠道。有关该公司及其产品的更多信息,请访问www.cytekbio.com。
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the flow cytometer and imaging products under the Amnis and Guava brands; the Cytek Orion reagent cocktail preparation system, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek headquarters are in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek Biosciences(纳斯达克: CTKB)是一家领先的细胞分析解决方案公司,通过使用其专利的全光谱分析(FSP)技术提供高分辨率、高内容和高灵敏度的细胞分析,推动下一代细胞分析工具的发展。Cytek的新方法利用发光信号整个光谱内的信息,以实现更高水平的多重检测精度和敏感度。 Cytek的FSP平台包括其核心仪器Cytek Aurora和Northern Lights系统;其细胞分选机Cytek Aurora CS;Amnis和Guava品牌下的流式细胞仪和成像产品;Cytek Orion试剂混合制备系统以及试剂、软件和服务,为其客户提供综合集成的解决方案套件。 Cytek总部位于加利福尼亚弗里蒙特,并在全球范围内设有办事处和分销渠道。有关该公司及其产品的更多信息,请访问www.cytekbio.com。
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek的产品仅供研究使用,不用于诊断程序(除了中国和欧盟的Cytek Northern Lights-CLC系统和某些试剂可用于临床使用)
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
Cytek,Full Spectrum Profiling,FSP,Cytek Aurora,Northern Lights,Cytek Orion,Amnis和Guava是Cytek Biosciences,Inc的商标。
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
除了向美国证券交易委员会(SEC)提交的文件,新闻稿,公开电话会议和网络广播外,Cytek还使用其网站(www.cytekbio.com),LinkedIn页面和X(以前是Twitter)帐户作为公司,产品的信息发布渠道,计划的财务和其他公告,参加即将到来的投资者和行业会议以及其他事项。此类信息可能被视为重要信息,Cytek可以使用这些渠道以遵守其在FD(法规FD)下的披露义务。因此,投资者应该监视Cytek的网站,LinkedIn页面和X帐户,同时关注它的SEC文件,新闻发布,公开电话会议和网络广播。
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
媒体联系人:
Stephanie Olsen
Lages&Associates
(949)453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
投资者联系人:
Paul Goodson
投资者关系主管
Cytek Biosciences
pgoodson@cytekbio.com